Infection virus (HCV) disease has quickly evolved from a “silent” chronic condition to danger to our healthcare system. The release of new oral drugs that have rendered HCV infection largely curable coincided with this change. Sofosbuvir, HCVadvocate the first straightforward antiviral medication, was authorized by Health Canada on December 13, 2013, following a protracted wait for better treatment. It is used in combination treatment for HCV genotypes. Ledipasvir-sofosbuvir, an oral combination drug that is well-tolerated and very efficient in the treatment of genotype infection, was authorized for use in Canada on October 15, 2014.
The cost of the drugs was widely criticized as being excessive, yet sofosbuvir’s estimated sales reportedly exceeded $10 billion in just the first year, making it one of the most successful medicine launches ever. Despite the fact anticipated that provincial governments would negotiate lower rates and that competition will eventually result in cheaper pricing, the sheer volume of prospective “clients” in the HCV treatment market promises to be a bonanza for pharmaceutical corporations.
Patients who had previously received assurances
And recommendations against interferon-based therapies due to their negative side effects are now being pushed to seek therapy. Pharmaceutical firms that provide HCV medications have a significant interest in assisting advocacy groups, hosting educational dinners for medical professionals, funding diagnostic tests, and participating heavily in conferences held both domestically and abroad. Organizations that formerly spearheaded the fight for access to HIV medicine are now concentrating on HCV treatments. Multidisciplinary facilities are being established for HCV care, and governments are under increasing pressure to provide a sizeable percentage of their medication expenditures to HCV therapy.
The development of safe, efficient oral treatments for HCV infection is a significant advance that will aid in avoiding the dangerous and potentially expensive side effects of end-stage liver disease. However, we urgently want a logical strategy for how these novel medications are administered to individuals with significant confounding health concerns. Humans must not lose track of the issues causing the HCV pandemic or scale down our support for the measures that might improve the health of individuals who are infected with the virus. The new wave of Hepatitis c among heroin injectors started. In large Canadian cities, the frequency of HCV infection has varied from 50% to 90% in this group for decades, which has led to a saturation of infection in the most vulnerable. The issue has gotten worse due to neglect on the side of the government and medical professionals toward injecting drug users. Efforts to restrict the spreading of HCV infection using harm-reduction initiatives have been thwarted by aggressive enforcement measures around the use of illegal drugs and a contemptuous social reaction to those who suffer from addictions.
